RxDoctor Payments Data

Kevin Voigt

Optometrist · Corpus Christi, TXNPI 1437509700

Payments from drug & device makers

$1,369in general payments, 2019–2025

Across 44 payments — averaging $31.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$425
  • Rxsight Inc$398
  • Alcon$156
  • Optos, Inc.$99
  • Dompe US, Inc.$89
  • Oyster Point Pharma, Inc.$45
  • plus $157 from 8 others

What the payments were for

  • Food & beverage$1,25291%
  • Education$181%
  • Entertainment$997%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,369 in reported general payments places this provider in the 60th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$189,691
Medicare patients
738
Services billed
2,586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine102$125,345
LumiganBimatoprost117$45,460
RocklatanNetarsudil Mesylat/Latanoprost52$21,891
RhopressaNetarsudil Mesylate50$20,566
XiidraLifitegrast12$18,148
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol123$15,341
Loteprednol Etabonate66$10,254
Cyclosporine18$9,535
CombiganBrimonidine Tartrate/Timolol38$9,069
Latanoprost769$7,206
Timolol MaleateTimolol Maleate/Pf11$6,717
SimbrinzaBrinzolamide/Brimonidine Tart24$4,946
Prednisolone Acetate117$4,865
Dorzolamide-TimololDorzolamide/Timolol/Pf29$4,122
Brimonidine Tartrate304$4,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$425$182,377268 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$18$42,457102 claims
AlconSimbrinza$156$4,94624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,315 optometrist providers in Texas.

Other optometrist in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →